Related Experiment Video
Updated: Jan 20, 2026

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
Published on: September 15, 2018
Src-Dependent DBL Family Members Drive Resistance to Vemurafenib in Human Melanoma
Charlotte R Feddersen1, Jacob L Schillo1, Afshin Varzavand2
1Department of Anatomy and Cell Biology, Carver College of Medicine, University of Iowa, Iowa City, Iowa.
Abstract:
The use of selective BRAF inhibitors (BRAFi) has produced remarkable outcomes for patients with advanced cutaneous melanoma harboring a BRAFV600E mutation. Unfortunately, the majority of patients eventually develop drug-resistant disease. We employed a genetic screening approach to identify gain-of-function mechanisms of BRAFi resistance in two independent melanoma cell lines. Our screens identified both known and unappreciated drivers of BRAFi resistance, including multiple members of the DBL family. Mechanistic studies identified a DBL/RAC1/PAK signaling axis capable of driving resistance to both current and next-generation BRAFis. However, we show that the SRC inhibitor, saracatinib, can block the DBL-driven resistance. Our work highlights the utility of our straightforward genetic screening method in identifying new drug combinations to combat acquired BRAFi resistance. SIGNIFICANCE: A simple, rapid, and flexible genetic screening approach identifies genes that drive resistance to MAPK inhibitors when overexpressed in human melanoma cells.
Insights
Drug resistance is common in melanoma patients treated with BRAF inhibitors. A genetic screen identified a DBL/RAC1/PAK signaling pathway driving this resistance, which can be blocked by saracatinib, offering new combination therapy options.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- Selective BRAF inhibitors (BRAFi) show efficacy in advanced cutaneous melanoma with BRAF mutations.
- Acquired drug resistance limits the long-term effectiveness of BRAFi therapy in most patients.
Purpose of the Study:
- To identify novel gain-of-function mechanisms driving BRAFi resistance in melanoma.
- To explore potential therapeutic strategies to overcome BRAFi resistance.
Main Methods:
- Utilized a genetic screening approach in two independent melanoma cell lines to identify resistance drivers.
- Conducted mechanistic studies to elucidate the function of identified resistance genes.
- Tested the efficacy of a SRC inhibitor (saracatinib) in blocking resistance.
Main Results:
- Identified known and novel drivers of BRAFi resistance, including DBL family members.
- Discovered a DBL/RAC1/PAK signaling axis mediating resistance to current and next-generation BRAFis.
- Demonstrated that saracatinib effectively inhibits DBL-driven BRAFi resistance.
Conclusions:
- A straightforward genetic screening method can rapidly identify genes conferring resistance to MAPK inhibitors.
- The DBL/RAC1/PAK pathway is a key mediator of acquired BRAFi resistance in melanoma.
- Saracatinib represents a potential therapeutic agent for combination therapy to overcome BRAFi resistance.
Related Concept Videos
Protein Families
Protein Families
Gene Families
Occasionally these regions can be adapted to take on new roles within the organism, becoming novel genes...
Gene Families
Family Therapy
Strategic Family Therapy
Strategic family therapy emphasizes resolving communication barriers and improving problem-solving abilities...
Energy to Drive Translocation
Generally, polypeptides are unfolded by two distinct...

